Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on XyloCor Therapeutics, Inc. — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

XyloCor Therapeutics and SmartCella Enter Licensing Agreement for Extroducer Infusion Catheter System

Jul 10, 2024•almost 2 years ago

Contract Type

agreement

WayneBiotechnology

Description

XyloCor Therapeutics, Inc. and SmartCella Holding AB have entered into a licensing agreement where XyloCor has obtained the rights to the Extroducer Infusion Catheter System for the delivery of its lead gene therapy candidate, XC001, directly into the heart for patients with refractory angina, aiming to offer improved safety and ease of delivery without surgery.

Company Information

Company

XyloCor Therapeutics, Inc.

Location

39 Addison Lane

Wayne, Pennsylvania, United States

About

XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.

Predictive Intelligence
Strategic

ML-powered predictions for XyloCor Therapeutics, Inc.'s next move

Learn about Strategic plan

Related People

Suggested for you

Sign in to view contact details

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months